Like most websites The Analytical Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Fields & Applications Pharma & Biopharma, Metabolomics & Lipidomics

The New 2D-LC Kids on the Block

sponsored by Agilent Technologies

The metabolomics master

Bernd Kammerer

Bernd Kammerer heads the metabolomics facility at the Center for Biosystems Analysis (ZBSA), University of Freiburg, Germany, the purpose of which is to identify and quantify the full range of metabolites in biological systems. Bernd has broad scientific experience in metabolite and metabolome analysis, particularly with MS and NMR methods, and is familiar with  bioinformatic methods for cluster analysis and metabolomic data mining.

What are the specific analytical needs of metabolomics?

Well, the complexity and high dynamic range of metabolite concentrations pose tough challenges for qualitative and quantitative analysis. Typically, the target compounds are small molecules with masses ranging between 100 and 1000 Da. These are studies in a wide variety of biological matrices, such as cell culture samples, urine and blood. On the one hand, you need precise MS analysis; on the other hand, a highly effective chromatographic separation is indispensible.

How has your view of 2D-LC changed over the last decade?

Ten years ago, 2D-LC was accomplished mainly by coupling the first and second dimensions offline. This provided fantastic separation power but it was very time-consuming, something that has been solved by modern 2D-LC systems. Today, it is possible to perform comprehensive 2D-LC without loss of time and with fewer potential sources of error.

What problem were you addressing when you first considered 2D-LC?

A major research project for us is the identification of a metabolic signature for early detection of human breast cancer. To do this, we are analyzing different biological samples with a high degree of complexity. Our target substances – modified nucleosides and ribosyl derivatives – differ only slightly in terms of their chemical structure and, therefore, retention in LC. Consequently, we decided to lift the chromatography to the next level, that is, to two-dimensional separation.

Metabolomics generally deals with complex matrices containing several hundred compounds, so separation power is essential. Insufficient separation can lead to the formation of highly reactive radical cations that interact with each other in the ion source (ESI or APCI) before entering the MS, causing ion suppression and artefacts. Since we are often looking to distinguish between two different biological states, it is important to improve the (semi-)quantitative analysis of target compounds, something that has particular relevance to ion suppression. An additional advantage of increased separation power is the possibility of determining previously hidden metabolites.

What were your expectations of 2D-LC?

Two things really. The structural class we deal with is differentially modified nucleosides, and we expected  to achieve a better differentiation between isomers and nucleosides that could hardly be separated at all using a single column. And we were hoping for purification of peaks in the second dimension separation to help limit background noise.

What has been your experience so far?

We have just started with the new technique and are in the process of method optimization. Choosing the right separation mechanism is the first step of method development. Column dimensions, solvents and elution gradients all offer many possibilities to improve your analysis and different combinations of column materials lead to striking differences in orthogonality, retention and peak capacity. Our 2D-LC can be used as a standalone solution with a diode array detector, but it can also be coupled to different mass spectrometers. This high degree of functionality and flexibility is important for studies of complex biochemical pathways.

Currently, we are looking forward to the first comprehensive measurements from a large batch of real life samples. The first results look very promising (see Figure 1).

Read the full article now

Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE and always will be!


Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Analytical Scientist magazine

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Rich Whitworth

Rich Whitworth completed his studies in medical biochemistry at the University of Leicester, UK, in 1998. To cut a long story short, he escaped to Tokyo to spend five years working for the largest English language publisher in Japan. "Carving out a career in the megalopolis that is Tokyo changed my outlook forever. When seeing life through such a kaleidoscopic lens, it's hard not to get truly caught up in the moment." On returning to the UK, after a few false starts with grey, corporate publishers, Rich was snapped up by Texere Publishing, where he spearheaded the editorial development of The Analytical Scientist. "I feel honored to be part of the close-knit team that forged The Analytical Scientist – we've created a very fresh and forward-thinking publication." Rich is now also Content Director of Texere Publishing, the company behind The Analytical Scientist.

Register to The Analytical Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Analytical Scientist magazine